Abstracts Archive - Page 857 of 2425 - ACR Meeting Abstracts

Abstract Number: 1479 • 2019 ACR/ARP Annual Meeting
Multi-Symptom Impact on the EQ5D Index in Bio-naïve Active Psoriatic Arthritis Patients: An Analysis Through Week 24 of the GO-VIBRANT Study
Alexis Ogdie¹, Nan Li ², Steve Peterson ², Chetan Karyekar ², Soumya Chakravarty ³, Shelly Kafka ⁴ and Jessica Walsh ⁵, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Janssen Global Services, LLC, Horsham, PA, ³Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Horsham; Philadelphia, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Division of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease characterized by peripheral arthritis, axial inflammation, dactylitis, enthesitis and skin and nail psoriasis. The impact of…
Abstract Number: 1480 • 2019 ACR/ARP Annual Meeting
Clinical Characteristics and Treatment Profiles of Patients with Ankylosing Spondylitis Who Initiated Secukinumab and Other Biologics: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Alexis Ogdie¹, Mei Liu ², Sabrina Rebello ², Meghan Glynn ³, Blessing Dube ², Robert McLean ³, Esther Yi ⁴, Yujin Park ⁵ and Philip Mease ⁶, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Waltham, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Pharmaceuticals Corporation, East Hanover, ⁶Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Secukinumab is the only non–tumor necrosis factor inhibitor biologic therapy approved for the treatment of ankylosing spondylitis (AS) in the United States. Patients with…
Abstract Number: 1481 • 2019 ACR/ARP Annual Meeting
Real-World Use of Apremilast in Combination with Biologic Therapy in Patients with Psoriatic Arthritis: Findings from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Alexis Ogdie¹, Mei Liu ², Meghan Glynn ³, Kelechi Emeanuru ², Leslie Harrold ⁴, Sven Richter ⁵, Benoit Guerette ⁵ and Philip Mease ⁶, ¹Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Waltham, ⁴Corrona, LLC and University of Massachusetts Medical School, Worcester, MA, ⁵Celgene Corporation, Summit, ⁶Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in adult patients with active PsA despite prior use of csDMARDs and/or biologics in phase…
Abstract Number: 1482 • 2019 ACR/ARP Annual Meeting
Secukinumab Provides Sustained Improvement of Enthesitis in Ankylosing Spondylitis Patients: A Pooled Analysis of Four Pivotal Phase 3 Trials
Georg Schett¹, Xenofon Baraliakos ², Filip Van den Bosch ³, Atul Deodhar ⁴, Lianne Gensler ⁵, Mikkel Østergaard ⁶, Shital Agawane ⁷, Ayan Das Gupta ⁷, Shephard Mpofu ⁸, Todd Fox ⁸, Adam Winseck ⁹, Brian Porter ⁹ and Abhijit Shete ⁸, ¹Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, ²Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ³Ghent University Hospital, Ghent, Belgium, ⁴Oregon Health & Science University, Portland, OR, ⁵University San Francisco California, San Francisco, CA, ⁶Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ⁷Novartis Healthcare Pvt Ltd, Hyderabad, India, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Enthesitis can be a debilitating spondyloarthritis (SpA) manifestation and the cause of pain, reduced quality of life and impaired physical function.1,2 Herein, we evaluated…
Abstract Number: 1483 • 2019 ACR/ARP Annual Meeting
Effect of Phosphodiesterase 4 Inhibition with Apremilast on Cardiometabolic Outcomes in Psoriatic Arthritis – Initial Results from the Immune Metabolic Associations in Psoriatic Arthritis (IMAPA) Study
Lyn Ferguson¹, Paul Welsh ¹, Rosemary Brown ¹, Alistair Tindell ², Sean Kerrigan ³, Naveed Sattar ¹, Iain McInnes ⁴ and Stefan Siebert ⁴, ¹Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Institute of infection, immunity and inflammation, Glasgow, ⁴Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) is associated with obesity and increased cardiometabolic risk. Weight loss has been noted in association with the phosphodiesterase 4 (PDE4) inhibitor…
Abstract Number: 1484 • 2019 ACR/ARP Annual Meeting
The Impact of Time Since First Diagnosis on the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis
Peter Nash¹, Maria Greenwald ², Liang-Hung Lin ³, Wei Yu ⁴, Paul Santos Estrella ⁵, Rajiv Mundayat ⁶, Daniela Graham ⁷ and Douglas Veale ⁸, ¹University of Queensland, Brisbane, Queensland, Australia, ²Desert Medical Advances, Palm Desert, CA, ³AIR, Taichung Tzu Chi Hospital, Taichung City, Taiwan (Republic of China), ⁴Pfizer Inc, Beijing, China (People's Republic), ⁵Pfizer Inc, Makati, Philippines, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT, ⁸EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland
Background/Purpose: Early identification, diagnosis, and treatment of psoriatic arthritis (PsA) is important in preventing long-term joint damage and disability, and the associated socioeconomic consequences.1 Tofacitinib…
Abstract Number: 1485 • 2019 ACR/ARP Annual Meeting
Secukinumab Provides Improvement in Nail Psoriasis and Inhibition of Radiographic Progression in Psoriatic Arthritis Patients with Nail Phenotype: 52-Week Results from a Phase III Study
Peter Nash¹, Philip Mease ², Bruce Kirkham ³, Alejandro Balsa ⁴, Atul Singhal ⁵, Erhard Quebe-Fehling ⁶, Luminita Pricop ⁷ and Corine Gaillez ⁶, ¹University of Queensland, Brisbane, Queensland, Australia, ²Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ³Guy's & St Thomas' NHS Foundation Trust, London, England, United Kingdom, ⁴Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain, ⁵Southwest Rheumatology, Dallas, TX, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Nail psoriasis (PsO) is present in up to 80% in psoriatic arthritis (PsA) patients (pts) and associated with significant pain, psychosocial disability, decreased physical…
Abstract Number: 1486 • 2019 ACR/ARP Annual Meeting
Infliximab Serum Trough Levels Predict Non-clinical Response in Patients with Axial Spondyloarthritis
Chamaida Plasencia¹, Ana Martínez-Feito ², Borja Hernández-Breijo ³, Victoria Navarro-Compán ⁴, Eva Olariaga-Mérida ³, Diana Peiteado ⁵, Alejandro Villalba ⁶, Irene Monjo ⁷, Laura Nuño ³, Cristina Diego ⁸, Dora Pascual-Salcedo ⁹ and Alejandro Balsa ¹, ¹Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain, ²Immuno-Rheumatology Research Group, IdiPAZ & Immunology Department. La Paz University Hospital, MADRID, Spain, ³Immuno-Rheumatology research group , Institute for Health Research (IdiPAZ), Madrid, Spain, MADRID, Spain, ⁴University Hospital La Paz, IdiPaz, Madrid, Spain, ⁵Hospital Universitario La Paz, Madrid, ⁶FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, ⁷FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, Spain, ⁸Immunology Unit, La Paz University Hospital, Madrid, Spain, MADRID, Spain, ⁹Immuno-Rheumatology Research Group, IdiPAZ. La Paz University Hospital, MADRID, Spain
Background/Purpose: Infliximab (Ifx) has proven to be efficacious for improving symptoms in patients with axial SpA(axSpA). Several factors may influence the pharmacokinetic-pharmacodynamic of Ifx and…
Abstract Number: 1487 • 2019 ACR/ARP Annual Meeting
Impact of TNF-α Inhibitor on Lipid Profile and Atherogenic Index of Plasma in Axial Spondyloarthritis: Two-year Follow-up Data from the Catholic Axial Spondyloarthritis COhort (CASCO)
Hong Ki Min¹, Seung-Ki Kwok ² and Sang-Heon Lee ¹, ¹Konkuk university medical center, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Background/Purpose: To evaluate the influence of TNF-α inhibitor on lipid profile and atherogenic index of plasma (AIP) in axial spondyloarthritis (axSpA) patients with long term…
Abstract Number: 1488 • 2019 ACR/ARP Annual Meeting
Ixekizumab Demonstrates Improvement Comparable to Adalimumab Across ACR Components in Biologic-Naïve Patients with Psoriatic Arthritis
M. Elaine Husni¹, Kristin Gowin ², Amanda Gellett ³, Aubrey Trevelin Sprabery ³, Cameron Helt ³, Vladimir Geneus ³ and Maurizio Rossini ⁴, ¹Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Asheville Arthritis & Osteoporosis Center, Asheville, NC, ³Eli Lilly and Company, Indianapolis, IN, ⁴University of Verona, Verona, Italy
Background/Purpose: In patients (pts) with active psoriatic arthritis (PsA) and inadequate response or intolerance to conventional synthetic DMARD (csDMARD), use of a biologic DMARD (bDMARD)…
Abstract Number: 1489 • 2019 ACR/ARP Annual Meeting
Impact of Apremilast on PsA Impact of Disease Core Components in Patients with a Limited Number of Active Joints: Results from a Real-World Study
Tim Jansen¹, Eric-Jan Kroot ², Arie van Vliet ³, Jan Pander ⁴ and Marijn Vis ⁵, ¹Viecuri MC, Venlo, Netherlands, ²Elkerliek, Helmond, Netherlands, ³Celgene, Utretcht, Netherlands, ⁴Celgene, Utrecht, Netherlands, ⁵ErasmusMC, Rotterdam, Netherlands
Background/Purpose: Recent data suggest that patients with moderately active psoriatic arthritis (PsA) and a limited number of active joints have a high likelihood of achieving…
Abstract Number: 1490 • 2019 ACR/ARP Annual Meeting
Blockage of TNFα and IL-12/23 Improves Depressive Symptoms in Patients with Psoriatic Arthritis – Analysis of Clinical Trial Data
Lihi Eder¹, Alexis Ogdie ² and Yujie Zhong ³, ¹Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, ²Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ³School of Statistics and Management, Shanghai University of Finance and Economics, Cambridge, China (People's Republic)
Background/Purpose: The prevalence of depression is increased in patients with psoriatic arthritis (PsA). Little is known about the impact of effective control of inflammation on…
Abstract Number: 1491 • 2019 ACR/ARP Annual Meeting
Long-term Clinical Outcome of Anti-TNF Treatment in Patients with Early Axial Spondyloarthritis: 10-year Data of the Etanercept vs. Sulfasalazin in Early Axial Spondyloarthritis Trial
Fabian Proft¹, Murat Torgutalp ², Anja Weiß ³, Mikhail Protopopov ⁴, Valeria Rios Rodriguez ⁵, Hildrun Haibel ¹, Olaf Behmer ⁶, Joachim Sieper ¹ and Denis Poddubnyy ⁷, ¹Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Germany and Ankara University Faculty of Medicine, Ankara, Turkey., Berlin, Germany, ³German Rheumatism Research Center (DRFZ), Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Germany, Berlin, Berlin, Germany, ⁵Charité Universitätsmedizin, Berlin, Germany, ⁶Pfizer Inc., Berlin, Germany, ⁷Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany
Background/Purpose: Long-term data on anti-TNF treatment in patients with early axial spondyloarthritis (SpA) is scarce. The objective of this analysis was to assess the long-term…
Abstract Number: 1492 • 2019 ACR/ARP Annual Meeting
Exposure-Response Analyses for Upadacitinib Efficacy and Safety in Ankylosing Spondylitis – Analyses of the SELECT-AXIS I Study
Mohamed Ismail¹, Ahmed Nader ¹, Insa Winzenborg ², In-Ho Song ³ and Ahmed Othman ¹, ¹AbbVie Inc., North Chicago, IL, ²AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany, ³AbbVie Inc., North Chicago, IL, USA, North Chicago, IL
Background/Purpose: Upadacitinib, a selective inhibitor of Janus kinase 1 (JAK1), is currently being evaluated for the treatment of several autoimmune disorders, including axial spondyloarthritis (axial…
Abstract Number: 1493 • 2019 ACR/ARP Annual Meeting
Improvement in the Signs and Symptoms of Psoriatic Arthritis with Ixekizumab Compared to Adalimumab in Patient Subgroups Defined by Baseline Disease Characteristics
Joseph Merola¹, Aubrey Trevelin Sprabery ², Amanda Gellett ², Chen-Yen Lin ² and Dennis McGonagle ³, ¹Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ²Eli Lilly and Company, Indianapolis, IN, ³University of Leeds, Leeds, United Kingdom
Background/Purpose: Multiple biologic DMARD (bDMARD) treatments are available for PsA, but there is limited research that compares the safety and efficacy of these treatments. Head-to-head…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].